InflaRx N.V. Common Stock
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.
Open IFRX dashboard ↗Kairos Pharma, Ltd.
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The company develops KROS 101, an orally available glucocorticoid-induced tumor necrosis factor receptor (GITR) ligand small-molecule antagonist to deplete regulatory T cells (Tregs) and activate effector T cells to augment the antitumor immune response for the treatment of patients with cancer, and a systemic immune modulator to address immunosuppressive activity of solid cancers; KROS 102, a GITR antagonist to increase the inhibitory regulatory Tregs functions; KROS 201 that activates the T cells using dendritic cells for the treatment of patients with glioblastoma; KROS 301, a tumor-targeting small molecule and checkpoint inhibitor with mechanisms of action resulting from blocking intranuclear localization of RelA, a key component of the NF-KB pathway, as well as targets tumor cells in RelA/p65 biomarker positive solid tumors; and KROS 401, a tumor microenvironment immune modulator and cyclic peptide inhibitor of IL-4 and IL-13 reversing tumor associated macrophage inhibition, and blocks the IL4/IL13 cytokine immune receptors for triple negative breast cancer. It also develops ENV 105, an antibody therapeutic for the prostate cancer patients resistant to androgen-targeted therapy, which is in Phase 2 clinical trial; and ENV 205, an antibody fragment that targets mitochondrial DNA. The company was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. Kairos Pharma, Ltd. was incorporated in 2013 and is based in Los Angeles, California.
Open KAPA dashboard ↗